PROTONIX

Clinical safety rating: caution

Comprehensive clinical and safety monograph for PROTONIX (PROTONIX).

How it works

Proton pump inhibitor that inhibits the H+/K+-ATPase enzyme system at the secretory surface of gastric parietal cells, blocking the final step of gastric acid secretion.

What the body does with it

Metabolism	Extensively metabolized in the liver via CYP2C19 and CYP3A4.
Excretion	Approximately 80% of a dose is excreted as metabolites in urine, with the remainder (≈20%) in feces via biliary elimination.
Half-life	Terminal elimination half-life is about 1–2 hours in healthy individuals; in CYP2C19 poor metabolizers or hepatic impairment, half-life may increase up to 3–6 hours, but clinical impact is minimal due to irreversible binding to H+/K+-ATPase.
Protein binding	≥96% bound to albumin and alpha1-acid glycoprotein.
Volume of Distribution	Apparent Vd is approximately 11–23 L (0.2–0.5 L/kg), indicating distribution into extracellular fluid; low Vd consistent with high protein binding.
Bioavailability	Oral bioavailability is about 77% (tablet) but decreases to ≈50% when taken with food; IV bioavailability is 100%.
Onset of Action	Oral: Onset of antisecretory effect within 2.5 hours; peak acid suppression at 3–4 days. IV: Onset within 15–30 minutes with maximal effect at 2–3 hours.
Duration of Action	Duration of acid suppression lasts approximately 24 hours after a single dose, allowing once-daily dosing; therapeutic effect persists for several days after discontinuation due to irreversible pump inhibition.

Classification & Brands

Dosing & administration

40 mg orally once daily; alternatively, 40 mg IV once daily for 7-10 days.

Dosage form	FOR SUSPENSION, DELAYED RELEASE
Renal impairment	No dose adjustment required for mild to moderate renal impairment (CrCl >20 mL/min). For severe renal impairment (CrCl <20 mL/min), maximum dose is 40 mg/day; consider reducing dose to 20 mg/day.
Liver impairment	In patients with Child-Pugh Class A or B: no dose adjustment required. In Child-Pugh Class C: maximum dose is 40 mg/day; consider reducing dose to 20 mg/day.
Pediatric use	Children 1-16 years: weight-based dosing; 1.2 mg/kg/day orally (max 40 mg/day) for up to 8 weeks; for IV, no established pediatric dosing; use with caution.
Geriatric use	No specific dose adjustment required; however, consider lower starting dose (20 mg/day) due to decreased hepatic and renal function with age.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

Comprehensive clinical and safety monograph for PROTONIX (PROTONIX).

Breastfeeding	Excreted in human milk in small amounts; M/P ratio unknown. No adverse effects reported in breastfed infants. Use with caution, especially for prolonged therapy.
Teratogenic Risk	Pregnancy Category B. No evidence of teratogenicity in animal studies. Limited human data; first trimester: no increased risk of major malformations reported. Second and third trimesters: no documented fetal harm. However, use only if clearly needed.
Fetal Monitoring

Warnings & precautions

■ FDA Black Box Warning

No FDA black box warning.

Side Effect Profile

Serious Effects

Absolute Contraindications

["Hypersensitivity to pantoprazole or any component of the formulation","History of hypersensitivity to other proton pump inhibitors","Co-administration with rilpivirine-containing products"]

Clinical Precautions

Precautions

["Gastric malignancy risk (symptomatic response does not preclude malignancy)","Acute interstitial nephritis","Cyanocobalamin (Vitamin B12) deficiency with long-term use","Hypomagnesemia, symptomatic and asymptomatic, especially with prolonged therapy","Clostridioides difficile-associated diarrhea (increased risk)","Bone fracture risk (hip, wrist, spine) with high-dose or long-term use","Cutaneous and systemic lupus erythematosus","Fondaparinux interaction (increased bleeding risk)"]

Clinical Tips & Counseling

Drug interactions

Loading safety data…

PROTONIX

Clinical safety rating: caution

Comprehensive clinical and safety monograph for PROTONIX (PROTONIX).

How it works

Proton pump inhibitor that inhibits the H+/K+-ATPase enzyme system at the secretory surface of gastric parietal cells, blocking the final step of gastric acid secretion.

What the body does with it

Metabolism	Extensively metabolized in the liver via CYP2C19 and CYP3A4.
Excretion	Approximately 80% of a dose is excreted as metabolites in urine, with the remainder (≈20%) in feces via biliary elimination.
Half-life	Terminal elimination half-life is about 1–2 hours in healthy individuals; in CYP2C19 poor metabolizers or hepatic impairment, half-life may increase up to 3–6 hours, but clinical impact is minimal due to irreversible binding to H+/K+-ATPase.
Protein binding	≥96% bound to albumin and alpha1-acid glycoprotein.
Volume of Distribution	Apparent Vd is approximately 11–23 L (0.2–0.5 L/kg), indicating distribution into extracellular fluid; low Vd consistent with high protein binding.
Bioavailability	Oral bioavailability is about 77% (tablet) but decreases to ≈50% when taken with food; IV bioavailability is 100%.
Onset of Action	Oral: Onset of antisecretory effect within 2.5 hours; peak acid suppression at 3–4 days. IV: Onset within 15–30 minutes with maximal effect at 2–3 hours.
Duration of Action	Duration of acid suppression lasts approximately 24 hours after a single dose, allowing once-daily dosing; therapeutic effect persists for several days after discontinuation due to irreversible pump inhibition.

Classification & Brands

Dosing & administration

40 mg orally once daily; alternatively, 40 mg IV once daily for 7-10 days.

Dosage form	FOR SUSPENSION, DELAYED RELEASE
Renal impairment	No dose adjustment required for mild to moderate renal impairment (CrCl >20 mL/min). For severe renal impairment (CrCl <20 mL/min), maximum dose is 40 mg/day; consider reducing dose to 20 mg/day.
Liver impairment	In patients with Child-Pugh Class A or B: no dose adjustment required. In Child-Pugh Class C: maximum dose is 40 mg/day; consider reducing dose to 20 mg/day.
Pediatric use	Children 1-16 years: weight-based dosing; 1.2 mg/kg/day orally (max 40 mg/day) for up to 8 weeks; for IV, no established pediatric dosing; use with caution.
Geriatric use	No specific dose adjustment required; however, consider lower starting dose (20 mg/day) due to decreased hepatic and renal function with age.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

Comprehensive clinical and safety monograph for PROTONIX (PROTONIX).

Breastfeeding	Excreted in human milk in small amounts; M/P ratio unknown. No adverse effects reported in breastfed infants. Use with caution, especially for prolonged therapy.
Teratogenic Risk	Pregnancy Category B. No evidence of teratogenicity in animal studies. Limited human data; first trimester: no increased risk of major malformations reported. Second and third trimesters: no documented fetal harm. However, use only if clearly needed.
Fetal Monitoring

Warnings & precautions

■ FDA Black Box Warning

No FDA black box warning.

Side Effect Profile

Serious Effects

Absolute Contraindications

["Hypersensitivity to pantoprazole or any component of the formulation","History of hypersensitivity to other proton pump inhibitors","Co-administration with rilpivirine-containing products"]